Hologic Stock Falls After Q3 Revenue Dip, But It Lifts Revenue and Profit Outlook
Hologic Inc (NASDAQ: HOLX) posted Q3 adjusted EPS of $0.93, down from $0.95 a year ago and beating the consensus of $0.88
Analyst Expectations for Hologic’s Future
Within the last quarter, Hologic (NASDAQ:HOLX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell
• Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
Hologic’s Earnings: A Preview
Hologic (NASDAQ:HOLX) is set to give its latest quarterly earnings report on Monday, 2023-07-31. Here’s what investors need…
Benzinga’s Top Ratings Upgrades, Downgrades For July 14, 2023
Upgrades For General Mills Inc (NYSE:GIS), Argus Research upgraded the previous rating of Hold to Buy. For the…
Expert Ratings for Hologic
Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Illumina Takes AI to Genomics: Launch of PrimateAI-3D for Accurate Disease Prediction
Illumina, Inc. (NASDAQ: ILMN) launched PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts disease-causing genetic mutations in patients.
Hologic Announces FDA Clearance Of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
Multiplexed Respiratory Test Now Available in the U.S. With New RespDirect Collection Kit
Hologic Inc. (NASDAQ:HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the
What 9 Analyst Ratings Have To Say About Hologic
Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Earnings Scheduled For May 1, 2023
Companies Reporting Before The Bell
• TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.37 per share on revenue of $3.38 million.